John L. Marshall, MD, on Issues of Value in Colorectal Cancer Treatment
2015 ASCO Annual Meeting
John L. Marshall, MD, of Georgetown University, discusses how the cost of care affects behavior and decision-making on the part of patients and oncologists.
Andrew James Martin, PhD, and Anthony J. Olszanski, RPh, MD
Andrew James Martin, PhD, of NHMRC Clinical Trials Centre, University of Sydney, and Anthony J. Olszanski, RPh, MD, of Fox Chase Cancer Center, discuss a form of vitamin B3 that reduced the incidence of new nonmelanoma skin cancers in high-risk patients (Abstract 9000).
Jedd Wolchok, MD, PhD, and Anthony J. Olszanski, RPh, MD
Anthony J. Olszanski, RPh, MD, of Fox Chase Cancer Center, and Jedd Wolchok, MD, PhD, of Memorial Sloan Kettering Cancer Center, discuss therapies for treatment-naive patients with advanced melanoma (Abstract LBA1).
Julie Vose, MD, MBA
Julie Vose, MD, MBA, of the University of Nebraska Medical Center, reflects on the 2015 Annual Meeting and her year ahead as ASCO President.
Asher Alban Chanan-Khan, MD
Asher Alban Chanan-Khan, MD, of the Mayo Clinic Cancer Center, discusses an important treatment option that significantly improved overall response rate and reduced risk of progression or death by 80% (Abstract LBA7005).
Dung T. Le, MD, and Axel Grothey, MD
Dung T. Le, MD, of Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, and Axel Grothey, MD, of the Mayo Clinic, discuss how mismatch repair status predicts clinical benefit of immune checkpoint blockade with pembrolizumab (Abstract LBA100).